SLNO Q2 2021 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

$2B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$11M

Net Income

-$11M

EPS (Diluted)

$-2.10

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$857,000

Balance Sheet

Total Assets

$49M

Total Liabilities

$21M

Stockholders' Equity

$27M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$11M	-$11M	+1.0%
Net Income	-$11M	-$7M	-48.8%